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Endothelium  has  been  thought  to  play  a  passive  role  in  hemostatic  and 
inflammatory phenomena.  Clinical and laboratory observations, however, have 
suggested  that  endothelium  can  play  an  active  role  in  the  response  of  the 
inflammatory and coagulation systems to perturbation and that these responses 
are linked. A  component of the delayed hypersensitivity response, for example, 
includes  induction  of procoagulant  activity (I).  The  Shwartzmann  reaction,  a 
basic phenomenon in the biology of bacterial infections, includes tissue infiltra- 
tion by leukocytes and prominent thrombotic pathology. Another example is the 
clinical  picture  of  systemic  lupus  erythematosus,  which  includes  a  vascutitic 
syndrome and  multiple  coagulation  abnormalities  in  addition  to  autoimmune 
phenomena (2). 
As a potent mediator of inflammatory and immunologic events (3-6), interleu- 
kin 1 (IL-1) 1 is likely to have a role in the physiology of these phenomena. Recent 
studies have shown that IL-1 can promote endothelial cell synthesis and expres- 
sion  of tissue  factor  (7),  a  cofactor in  the  initiation  of coagulation  (8).  Once 
activation of coagulation is initiated on the cell surface, endothe]ium can promote 
an entire pathway of coagulation leading to the formation of fibrin (9). Further- 
more, three recent reports have suggested that IL-1 can be produced by endo- 
thelium (10-12).  These findings  have prompted us to consider the hypothesis 
that IL-1 is an integral part of the endothelial cell response to injurious stimuli. 
If this were true,  then endothelial cell IL-!  could exert a  regulatory effect on 
inflammatory phenomena  while  simultaneously  inducing procoagulant  activity 
in the vessel wall. 
These considerations have led us to study factors that influence the production 
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of IL-1  by endothelial cells. The results indicate that cultured human umbilical 
vein endothelial  cells treated  with  lipopolysaccharide synthesize and  elaborate 
enhanced  amounts  of IL-1.  In  addition,  the  coagulation  enzyme thrombin,  a 
physiological  vessel  wall  perturbant  generated  by  the  activated  coagulation 
system,  induced comparable amounts  of IL-1  activity.  The generation  of IL-1 
by  perturbed  endothelium  indicates  a  new  mechanism  by  which  the  systems 
involved  in  coagulation  and  inflammation  can  influence  each  other  via  the 
endothelium. This emphasizes the regulatory role that endothelium can play in 
coagulation and inflammation. 
Materials and Methods 
Cell Culture.  Endothelial cells derived from human umbilical cord veins were prepared 
according to the method ofJaffe et al.  (13,  t4) as modified by Thornton et al. (15).  In 
brief, after harvesting endothelial cells from umbilical veins, the cells were added to tissue 
culture flasks pretreated with gelatin (0.2%) (gelatin solutions contained polymyxin B at 
1 /~g/ml) and grown in medium 199 (Gibco Laboratories, Grand Island, NY), containing 
heparin (90 #g/ml; Sigma Chemical Co., St.  Louis, MO), endothelial cell growth factor 
(20 /~g/ml;  Meloy Laboratories, Springfield, VA),  human  serum (10%; prepared from 
normal  human  volunteers), fetal  calf serum  (10%;  Sterile Systems,  Logan,  UT),  and 
penicillin-streptomycin (50 U/ml-50 •g/m];  Gibco Laboratories). Where indicated, fibro- 
nectin was used as a substrate for cell growth in place of gelatin. The cells were grown at 
37°C in a humidified atmosphere with COJair (5%/95%). At confluence (1.0-1.3 x  10  ~ 
cells/cm2),  cells  were prepared for subculture  with trypsin-EDTA (0.25-0.05%;  Gibco 
Laboratories). Cultures  were  characterized as  endothelial  cells  based  on  morphologic 
criteria (13) and by positive immunofluorescent staining (16) with a specific anti-factor 
VIII/yon Willebrand factor antibody (generously provided by Drs.  Chopek and Davie, 
University of Washington, Seattle, WA). Endothelial cell cultures contained no monocyte/ 
macrophage-contaminating cells, as judged by morphologic criteria and by cytofluorom- 
etry using OKM2, a monoclonal antibody reactive with the majority of human monocytes/ 
macrophages (17). Absence of OKT3-positive cells (18) by cytofluorometry  of endothelial 
cell cultures indicated that T  lymphocytes were not present. 
Bovine aortic endothelial cells were grown from aortae of newborn calves as described 
(19) and were used from passages  2-6.  Bovine capillary adrenal cells,  prepared by the 
method of Folkman (20), were provided by Drs. Furie and Silverstein (Columbia Univer- 
sity, New York) at passage 4 (21). 
Treatment of Endothelial  Cells with Endotoxin  and Thrombin.  Experiments were carried 
out in 35-mm tissue culture dishes 24 h after endothelial cells reached confluence, using 
primary cultures and serially passaged  cells  (passages  1-18).  Monolayers were washed 
three  times  with  Hanks'  balanced  salt  solution  (Gibco  Laboratories), and  then  fresb 
medium 199 (1  ml/dish) with fetal calf serum (2%) and endotoxin (a phenolic extract of 
Escherichia coli serotype 026:B6; Sigma Chemical Co.) were added. In experiments using 
cycloheximide (1  #g/ml; Sigma Chemical Co.), this inhibitor was added simultaneously 
with the endotoxin. Culture supernatants were harvested at the indicated times, centri- 
fuged  to  remove cellular debris,  filtered (0.22  t~m), and  assayed  for  IL-1  activity as 
described below. Throughout these experiments, endothelial cell viability was >95%, as 
assessed  by trypan blue exclusion. When thrombin or modified thrombins were used as 
the perturbing agents in place of lipopolysaccharide, the incubation medium contained 
only medium  199 with bovine serum albumin  (fatty acid free) (0.5%; Sigma Chemical 
Co.) and polymyxin B (1 #g/ml; Pfizer, Inc., New York). Experiments using bovine aortic 
and capillary endothelial cells were carried out by the same protocols as outlined above. 
Rabbit  anti-human  IL-1  antibody  was  prepared  and  coupled  to  Sepharose  4B  as 
described previously (22). IgG from nonimmune animals was prepared similarly and also 
coupled to Sepharose 4B. The lgG-Sepharose columns were equilibrated with medium STERN  ET  AL.  1225 
199 containing bovine serum albumin (fatty acid free) (0.5%) and polymyxin B (1 ~g/ml) 
before use. 
IL-1 and IL-2 Assays.  IL-1 activity was measured in a costimulator assay using routine 
thymocytes as described previously (23). In brief, thymocytes (1.5 ×  106/well)  from 4-8- 
wk-old C3H/HEJ mice (The Jackson Laboratory, Bar Harbor, ME) were cultured for 72 
h in Iscoves modified Dulbecco's medium (Gibco Laboratories) containing fetal calf serum 
(10%), glutamine (1%),/3-mercaptoethanol (50 t~M), and phytohemagglutinin (1%).  Su- 
pernatant (50 #l) from stimulated endothelial cells was added to each well at the start of 
a  72  h  assay, and  [3H]thymidine (1  uCi/well;  New England  Nuclear,  Boston,  MA) was 
added 18 h before harvesting. Before assaying supernatants of endothelial cells containing 
added cycloheximide, samples were extensively dialyzed vs. saline (dialysis  tubing had a 
molecular weight cut-offof  3,500). Control samples containing cycloheximide and medium 
not exposed to cells were also dialyzed and assayed. Under these conditions cycloheximide 
had no effect on thymocyte proliferation in response to added IL-1 (Genzyme, Boston, 
MA). In addition  to studying culture supernatants, a lysate of endothelial cells was also 
assayed. The lysate was prepared by three freeze-thaw cycles (-80 to 37°C) and cellular 
debris was removed by centrifugation (10,000 g  for 20  rain).  Samples were assayed in 
triplicate. Lipopolysaccharide, up to  100 t~g/ml,  did not induce thymocyte proliferation 
above background in this assay. 
Culture supernatants containing added thrombin were treated with a  100-fold molar 
excess of purified bovine antithrombin III (see below) to inactivate any residual thrombin 
activity. Thrombin, however, even at the highest  doses used (40-50  U/ml) had only a 
minimal effect on the thymocyte proliferation assay. The latter effect was abrogated by 
the addition of antithrombin III. Antithrombin III alone did not induce proliferation of 
murine thymocytes or affect proliferation of thymocytes induced by purified IL-1 (Gen- 
zyme). Antitbrombin  III and diisopropyl fluorophosphate had no effect on endotoxin- 
induced  IL-1 elaboration by endothelial cells (see below). DIP-a-thrombin, 3,-thrombin, 
and ~-Phe-Pro-Arg-CH2-a-thrombin (see below) had no direct effect on the thymocyte 
proliferation assay at the concentrations used in these experiments. 
IL-2 activity was assessed by measuring proliferation of the murine  IL-2-dependent 
CTLL-2 line (the characteristics of this cell line have been previously described) (24-25) 
induced by addition of supernatants from stimulated and control endothelial cells.  The 
assay was carried out by incubating CTLL-2 cells 004 ceils per well) in the presence or 
absence of endothelial cell supernatants for 48 h, then adding [3H]thymidine (1 #Ci/well) 
and  harvesting  18  h  later.  No  IL-2  activity  was  detectable  in  control  or  stimulated 
endothelial cell supernatants. 
Preparation of Coagulation Proteins and Tissue Factor Assay.  Human factors IX (250 U/ 
rag) and  X  (130  U/mg) were purified to homogeneity from plasma by the method of 
DiScipio et al. (26). Factor IX was activated, as previously described (27), during incubation 
with factor XL coupled to Sepharose in the presence of CaCl2 (5 mM) for 45 rain at 37 °C. 
Factor X was activated during incubation with the coagulant protein from Russell's viper 
venom coupled to Sepharose in  the presence of CaClz (5  raM) for 30  rain at 37°C  as 
previously described (28).  In each case activation appeared complete by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis. Human prothrombin and human factor VIL 
were purified to homogeneity, as described previously (29-30).  Bovine antithrombin III 
(inhibitory activity of 1.0 U thrombin/#g) was purified to homogeneity by the method of 
Mahoney et al. (31).  Human a-thrombin (2.5  NIH U/#g) was purified as described (32). 
a-Thrombin was inactivated by incubation with diisopropylfluorophosphate (33) (2 mM 
at pH 7.5; Calbiochem-Behring Corp., San Diego, CA) for 20 min at 37°C. The reaction 
mixture  was then  dialyzed  extensively vs.  Hepes-saline [10  mM  (pH  7.4)/0.14  M].  A 
coagulant assay (34) indicated no residual thrombin activity. Thrombin (0.15 #g/ml) was 
also completely inactivated by antithrombin I II (250 ug/ml) after 10 min at 37 °C (35). 7- 
Thrombin and D-Phe-Pro-Arg-CHz-a-thrombin were prepared as described (36). 
Tissue factor activity of endothelial cell monolayers was assessed after washing the cells 
three times in Hepes-saline by adding factor VIL (0.5 nM) and factor X (300 nM) in  10 
mM Hepes (pH 7.4),  137 mM NaCI, 4 mM KC1, 11  mM glucose, 2.5 mM CaCI2, 2 mg/ 1226  ENDOTHELIAL  CELL  ELABORATION  OF  INTERLEUKIN  1 
ml bovine serum albumin at 37 °C. Aliquots of the reaction mixture supernatant (0.1  ml) 
were withdrawn at 7 rain, diluted in 0.5 ml of 50 mM Tris-HCl (pH 7.8),  175 mM NaCI, 
0.5  mg/ml  ovalbumin,  10  mM  EDTA,  and  assayed for  factor  Xa  amidolytic activity. 
Amidolytic activity was measured using the synthetic substrate Bz-Ile-Glu-Gly-Arg-pNA 
(0.5 mM) by monitoring the increase in absorbance at 405  nM (37). The concentration 
of factor X, formed was determined by comparison with a factor Xa standard as described 
previously (28).  Under these conditions, factor Xa formation was linear and limited only 
by the amount of tissue factor present. Before assaying cells treated with thrombin, the 
added thrombin  was neutralized by excess antithrombin  III and monolayers were then 
washed to remove antithrombin III. Similar results were observed when dansylarginine 
N-(3-ethyl-l,5-pentanediyl)amide, a specific thrombin inhibitor (38), replaced antithrom- 
bin III. 
Results 
Incubation  of cultured  human  umbilical  vein endothelial  cells with  lipopoly- 
saccharide resulted in the elaboration of IL-1 activity (Fig.  1).  The IL-1 activity 
of supernatants  from lipopolysaccharide-treated  endothelial  cells was easily de- 
tectable  up  to  a  1:32  dilution  in  the  murine  thymocyte  costimulation  assay. 
Although  the thymocyte assay was sensitive for the detection of endothelial  cell 
IL-1  activity,  to  better  characterize  the  molecular  species  in  the  supernatants 
causing  the  proliferative  response,  we  used  an  affinity  column  with  anti-IL-1 
antibody coupled to Sepharose (Fig.  2). Chromatography of lipopolysaccharide- 
treated  endothelial  cell  supernatants  on  the  anti-IL-1  column  removed  their 
proliferative activity in the thymocyte assay. A control column, with nonimmune 
IgG  coupled  to  the  resin,  had  no  effect  on  IL-l-like  activity  in  the  culture 
supernatants. 
Generation  of IL-1  activity was dependent  on  the  concentration  of lipopoly- 
saccharide  added,  increasing  steadily  from  10  ng/ml  to  10  ~g/ml  and,  soon 
thereafter,  reaching an apparent  maximum (Fig.  3A).  IL-1  found in the super- 
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FIGURE  1.  Elaboration of IL-I activity by lipopolysaccharide-treated endothelial cells. En- 
dothelial cell monolayers (passage 3) were incubated with medium 199 (1 ml) containing fetal 
calf serum (2%) in the presence or absence (C) of lipopolysaccharide (20 #g/ml) for 17 h at 
37°C. Samples from lipopolysaccharide-treated cells were diluted in medium as indicated and 
assayed for IL-1 activity in the thymocyte proliferation assay. Samples from untreated cells (C) 
were assayed at a 1:4 dilution (identical results were abserved at I : 1 and 1:8 dilutions). Sample 
dilution is plotted  vs. [~H]thymidine incorporation.  The mean +  1 SD of triplicate determi- 
nations is shown. STERN  ET  AL.  1227 
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FIGURE 2.  Effect  of anti-lL-1  column  on  the  IL-1  activity  of  lipopolysaccharide-treated 
endothelial cell  supernatants.  Endothelial cell  monolayers (passage  4)  were  incubated with 
medium  199 (1 ml) containing fetal calf serum (2%) in the presence of endotoxin (10 ~g/ml) 
for  18 h  at 37°C.  Aliquots of culture supernatants (0.2 ml) were then chromatographed on 
an anti-lL-1 column (bed volume, 0.8 ml) or a column made by coupling nonimmune rabbit 
IgG to the resin (bed volume, 0.8 ml). The initial culture supernatant (A), pass-through fraction 
from the anti-IL-1  column (B), and pass-through fraction from the control IgG column (C) 
were assayed in the thymocyte proliferation assay. The mean _+ 1 SD of triplicate determina- 
tions is shown. 
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FIGURE 3.  Dose dependence and time course of lipopolysaccharide-induced elaboration of 
1L-I  activity by endothelial cells. (A) Dose dependence, Endothelial cell monolayers (passage 
2) were incubated for 16 h at 37°C with medium 199 containing fetal calf serum (2%) in the 
presence of the indicated concentrations of lipopolysaccharide. Samples were then assayed in 
the thymocyte proliferation assay. The direct effect of lipopolysaccharide (20 gg]ml) added to 
the  thymocyte assay in  the absence of endothelial cell supernatant is shown (a).  (B) Time 
course.  Endothelial cell  monolayers were  incubated in  the presence  (0)  or absence (O)  of 
lipopolysaccharide (10 ug/ml) for the indicated times at 37°C.  The supernatants were then 
assayed  for  IL-1  activity  in  the  thymocyte  proliferation assay  as  described.  The  mean  of 
triplicate determinations is shown in A and B above. 
natant was not due to release from a preformed intracellular pool since lysates 
of endothelial cells not treated with lipopolysaccharide did not have significant 
I L-1 activity. To investigate whether protein synthesis was required for induction 
of IL-1  release, we added cycloheximide to cultures during lipopolysaccharide 
stimulation (Fig. 4).  Inhibition of IL-1  production was observed in the presence 
of cycloheximide (1 ug/ml), indicating that new protein synthesis was required. 
Comparable  lipopolysaccharide-induced generation of IL-1  activity was  ob- 
served with  endothelial  cells  from  four different vessels,  using  both  primary 
cultures and  serially passaged  cells (passages  1-18).  Furthermore, endotoxin- 
treated bovine aortic and capillary endothelial cells also generated IL-1 activity, 
though  the amounts were lower (~30%)  than  that  observed with the  human 
umbilical vein endothelial cells (data  not  shown).  Elaboration  of IL-1  activity 
occurred in a  time-dependent manner after the addition of lipopolysaccharide 
to endothelial cultures (Fig. 3B). IL-1 activity steadily increased up to 16 h and 1228  ENDOTHELIAL  CELL  ELABORATION  OF  INTERLEUKIN  1 
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FIC, UeE  4.  Effect of cyclobeximide on lipopolysaccharide-induced IL-I  elaboration.  Endo- 
thelial cells (passage  6) were  incubated  with  medium  199-fetal calf serum  (2%) alone (A), 
containing lipopolysaccharide (10 pg/rnl) in the presence of cyclobeximide (1 ~g/ml) (B), or 
containing only endotoxin (10 pg/ml) (C). This concentration of cyclobeximide did not reduce 
cell viability. Culture supernatants were dialyzed extensively vs. saline and assayed for IL-1 as 
described. Addition of lipopolysaccharide (10 ~g/ml) directly to the IL-1 assay (D) resulted in 
little thymocyte proliferation. Cycloheximide (1  pg/ml), after dialysis,  bad  no effect on the 
thymocyte proliferation assay (E). The mean -+ 1 SD is shown. 
then  reached  a  plateau.  In contrast,  control  endothelial  cell cultures  in  media 
alone maintained a low level of IL-1 activity. 
Since endothelial cells do not usually interact with lipopolysaccharide, we asked 
if any more physiological molecules could induce endothelial  cell IL-1  elabora- 
tion.  Prompted  by recent  studies  demonstrating  specific interactions  between 
endothelium and coagulation  factors (9, 28, 40-45), we examined the effect of 
a  variety of coagulation proteins on endothelial  cell IL-1  elaboration (Table I). 
These studies were carried out in serum-free medium to prevent inactivation of 
activated coagulation factors by inhibitors present in serum, such as antithrombin 
IlI.  Coagulation  factors normally present in plasma,  i.e., the zymogens, factors 
IX,  X,  and  prothrombin  (added  at  plasma  concentrations),  did  not  induce 
generation  of IL-1  activity by endothelial cells. Although  the activated form of 
factors IX (IXa) and X  (Xa), induced no or only small amounts of IL-1  release, 
respectively, thrombin  induced  elaboration  of significant  amounts  of IL-1.  To 
further study the effect of thrombin on endothelial cell elaboration of IL-1, we 
used thrombins modified at specific sites (Table II). Native ~-thrombin  induced 
elaboration of IL-1  endothelium, but tbrombin inactivated by antithrombin  III 
was no longer effective. Since antithrombin  III is a relatively large molecule (M~ 
~58,000)  (31,  35)  compared  with  thrombin  (Mr  -36,500)  (32),  the  inhibitor 
could be masking muhiple sites on the enzyme in addition to the active site. This 
led us to examine the effect of other forms of thrombin. ~{-thrombin (36), a form 
of thrombin  deficient  in  procoagulant  activity  but  which  retains  estero]ytic 
activity, was less effective than  c~-thrombin in the induction of IL-1. D-Phe-Pro- 
Arg-CH2-c~-thrombin  (36),  which  is  modified just adjacent  to the catalytic site 
within  the  fibrinopeptide  groove  (39),  did  not  induce  endothelial  cell  IL-I 
elaboration.  Consistent  with  this  data,  which  suggests  the  importance  of the 
active site region  of o~-thrombin,  we found  that  DIP-a-thrombin,  which  has  a 
blocked catalytic center, was ineffective in the induction of endothelial cell IL-1. 
Endothelial  cell  IL-1  elaboration  induced  by c~-thrombin  was dependent  on 
the concentration  of enzyme added and  the incubation time (Fig.  5). The time 
course of IL-1 elaboration was comparable to that observed with lipopolysaccha- STERN  ET  AL.  1229 
TABLE  I 
Effect of Coagulation Factors on the Generation of lL-I Activity by 
Endothelial Cells 
[3H]Thymidine incorpora- 
Coagulation factor  Concentration  tion 
ug/ml  cpm 
Factor IX  5  1,389 +  76 
Factor IX~  1  1,312 __- 111 
10  1,294 +- 68 
Factor X  10  1,517 _  163 
Factor Xa*  1  3,781  _+ 265 
10  5,088 _+ 460 
Prothrombin  100 
c~-Thrombin  0.2 
2 
No addition 
11,483 _+ 1,083 
13,382 +_ 1,165 
1,301  +_ 91 
Endothelial cells (passage 3) were incubated with medium 199 containing 
bovine serum albumin (0.5%) and polymyxin B (1 gg/ml). Then coagu- 
lation factors at  the indicated concentrations were added  for  16  h  at 
37 ° C. Cultures containing factor X~ and thrombin were incubated with 
antithrombin  Ill (400 ug/ml) for 10 rain at 37°C and then all samples 
were assayed in the thymocyte proliferation assay. The mean _  1 SD is 
shown. 
* Factors  IX~  and  Xa  are  the  activated  forms  of  factors  IX  and  X, 
respectively. 
TABLE  II 
Effect of a-Thrombin  and Modified Thrombins on the Induction of 
IL-1 Activity in Endothelial  Cells 
[SH]Thymidine 
Coagulation factors added  incorporation 
cpm 
a-Thrombin  11,688 +  971 
a-Thrombin-antithrombin  lit  1,264 +  131 
~-Thrombin  4,298 +__ 385 
D-Phe-Pro-Arg-CHz-a-thrombin  1,460 +- 78 
D1P-ee-thrombin  1,300 -+ 35 
Endothelial cells (passage 6) were incubated with medium  199 containing 
fetal calf serum (2%)  and polymyxin B (1  mg/ml). One of the following 
thrombins was added  for  16 h  at 37°C: a-Thrombin (0.3  U/ml or 0.12 
ug/ml), a-thrombin (0.15 #g/.ml) inactivated by antithrombin lit (250 ~g/ 
ml),  ~-thrombin  (0.2  ug/ml),  ~Phe-Pro-Arg-CH2-c~-thrombin  (0.18  ug/ 
ml), and DIP-c~-thrombin (0.11  ug/ml). Samples were assayed in a thymo- 
cyte proliferation assay. Control endothelial cell monolayers not incubated 
with  any  form  of thrombin  incorporated  1,400  ___  350  cpm  of [3H]- 
thymidine.  Modified forms of thrombin  were prepared  as described  in 
Materials and Methods. 
ride.  Although  the  amount  of  thrombin  causing  optimal  IL-1  elaboration  is 
relatively  high,  IL-1  is  generated  at  lower  concentrations,  which  may  occur  as 
prothrombin  is generated  on the endothelial  cell surface (9, 28,  43).  IL-1 activity 1230  ENDOTHELIAL  CELL  ELABORATION  OF  INTERLEUKIN  1 
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FIGURE 5.  Elaboration  of IL-1  activity  by endothelial  cells treated  with  c~-thrombin. (A) 
Dependence on dose of a-thrombin. Endothelial  cell monolayers (passage 5) were incubated 
for 16 h at 37°C with medium 199 (1 ml) containing 0.5% bovine serum albumin, polymyxin 
B (1 gg/ml), and the indicated concentrations of thrombin. A 100-fold molar excess of bovine 
antithrombin III was then added to each culture dish for 10 rain at 37°C and supernatants 
were assayed in the thymocyte proliferation assay. The direct effect of thrombin (50 U/ml), 
in the absence of endothelial  cell supernatants,  on proliferation  in the thymocyte assay is shown 
(a). (B) Time course of a-thrombin-induced elaboration  of IL-1. Endothelial  cell monolayers 
were  incubated  for the indicated  times at  37°C with medium  199 (1  ml) containing 0.5% 
bovine serum albumin  (fatty  acid  free) and polymyxin  B (1  #g/ml) in  the presence  (0) or 
absence (I) of thrombin (5 U/ml). Antithrombin Ill (0.8 rnM) was added for 10 rain and then 
supernatants  were assayed in the thymocyte proliferation  assay. The mean + SD is shown. 
produced  by endothelial  cells  in  response  to thrombin  could be removed  from 
culture  supernatants  by the  anti-IL-1  column,  as described  previously  for lipo- 
po]ysaccbaride-induced IL-1 activity (Fig. 2). Thrombin-induced  IL-1 generation 
was not due to lipopolysaccharide in the preparation since addition of antithrom- 
bin  III or  treatment  of the  enzyme  with  diisopropyl  fluorophosphate  blocked 
the  enzyme's  effect.  Furthermore,  treatment  of lipopolysaccharide  with  anti- 
thrombin  III  or  diisopropyl  fluorophosphate  under  these  conditions  did  not 
affect endotoxin-induced  IL-1 elaboration. 
These  results  indicate  that  a  potent  procoagulant  enzyme,  thrombin,  can 
induce  IL-1  in  a  highly  specific  manner.  Since  IL-1  is  known  to  induce  tissue 
factor activity  in  cultured  endothelial  cells  (7),  this  suggested  the  possibility  of 
self-regulation  of procoagulant  events  on  the  endothelial  cell  surface.  To  test 
this hypothesis,  IL-l-containing supernatants  from endothelial cells treated with 
thrombin  were  incubated  with  fresh  cultures,  after  the  residual  thrombin  was 
inactivated,  and induction of tissue factor activity was tested (Fig. 6).  Procoagu- 
lant activity, characterized as tissue factor based on the factor VIIa dependence 
of factor X  activation (8), was induced in endothelium.  Similar induction of tissue 
factor activity was observed when cultures were incubated with exogenous IL-1 
(Fig. 6). The ability of both a-thrombin-treated  endothelial cell supernatants  and 
exogenous  IL-1  to  induce  tissue  factor  in  endothelial  cells  was  prevented  by 
chromatography of the samples on the anti-IL-1-Sepharose column. 
Discussion 
The results reported here indicate that cultured endothelial cells elaborate IL- 
l  in  response to perturbation.  Generation  of IL-I  activity in response  to endo- 
toxin suggests  that endothelium  participates  in the regulation  of inflammatory/ STERN  ET  AL  1231 
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FIGURE 6.  Effect  of culture  supernatants from  thrombin-treated endothelial cells on  the 
procoagulant activity of fresh endothelial cell cultures.  Human  endothelial cell monolayers 
(passage 3) were treated with a-thrombin (10 U/ml) in medium 199 containing bovine serum 
albmnin (0.5%) and polymyxin B (1 txg/ml) for 8 h at 37°C. After this incubation period the 
supernatant (endothelial cell-conditioned medium) was incubated with antithrombin III  (2 
uM) (10 min at 37°C) to inactivate residual thrombin, filtered (0.22 t~m), and added to fresh 
endothelial cells for 6  h. Monolayers were washed and then 1 ml of 10 mM Hepes (pH  7.4) 
containing 137 mM NaCI, 4  mM KCI,  11  mM glucose, 2.5 ml CaCI~, 2 mg/ml bovine serum 
albumin, along wtih human factor Vlla (0.5 nM) and/or factor X  (300 nM), was added for 7 
min at 23°C.  The reaction mixture was assayed for factor Xa amidolytic activity using the 
synthetic peptide substrate Bz-lle-Glu-Gly-Arg-p-nitroanilide (0.5 mM). The amount of factor 
Xa formed after 7 rain (mean _+ SEM) is shown. (A) Endothelial cell-conditioned medium was 
incubated with the cells and factor Xa formation was assessed in the presence of factors VIIa 
and X. (B) Endothelial cell-conditioned medium was incubated with the cells and factor X~ 
formation was assessed in the presence of factor X alone. (C) Medium 199 containing thrombin 
(10 U/ml) was incubated for 8 h  in a glass tube and then antithrombin III (2 #M) was added 
to inactivate the thrombin. This medium (1  ml) was then incubated with the cells for 6  h  at 
37°C  and  factor  Xa  formation was assessed  in the  presence of factors  VII~ and  X.  (D,  E) 
Medium 199 containing purified exogenous IL-1 (5 U/ml, D; I U/ml, E) (supplied in 5% fetal 
calf serum) was incubated with endothelial cells, and factor Xa formation was assessed in the 
presence of factors VII~ and X. The mean and SEM of triplicates are shown. 
immunologic  phenomena.  The  induction  of endothelial  cell  IL-1  activity  by 
thrombin  indicates a  link between activation  of the coagulation system and the 
regulatory role of the endothelial cell. Although quiescent endothelium does not 
induce activation  of coagulation,  perturbation  of endothelial  cells in vitro by a 
variety of agents,  including  IL-1,  can  lead to the  induction  of tissue factor,  a 
cofactor for the initiation of coagulation (8).  Endothelial cell tissue factor, in the 
presence  of  factor  VII/VIIi,  results  in  the  activation  of factors  IX  and  X, 
propagating a procoagulant pathway on the cell surface that leads to the gener- 
ation of thrombin (9, 28). Thrombin may then function as a coagulation enzyme 
or as a regulator of endothelial cell function, including the elaboration of IL-1. 
IL-1, finally, promotes the synthesis and expression of additional endothelial cell 
tissue factor. Although  multiple pathways are operative in inhibiting  thrombin 
procoagulant activity in the plasma and on the endothelial  cell surface (28,  33, 
35, 44-47), thrombin-induced  IL-1  generation represents a cellular mechanism 
by which this enzyme can potentially promote procoagulant events. 
The induction of IL-1 activity by thrombin was specific for the enzyme (Tables 
I and  II) and required an  intact catalytic center.  Thus,  DIP-o~-thrombin and D- 
Phe-Pro-Arg-o~-thrombin  (36) did not  induce  IL-1  elaboration  but a-thrombin 
did (Table  II).  3,-thrombin,  in  which  the fibrin  exosite region  is blocked (39), 
was able to induce IL-1, though  less effectively than  the intact enzyme. This is 1232  ENDOTHELIAL  CELL ELABORATION OF  INTERLEUKIN 1 
consistent  with  many  of  thrombin's  cellular  actions,  such  as  stimulation  of 
mitogenesis (48) and  prostaglandin  synthesis (49),  but differs from thrombin's 
role as a chemotactic agent (39) in which DIP-a-thrombin is even more effective 
than  the active enzyme. Thrombin-induced  IL-1  generation  may be related  to 
the previously described (45) class of irreversible endothelial  cell binding  sites 
specific for the enzyme. Other mechanisms may be involved, such as thrombin- 
protease  nexin  complexes  (50)  or  thrombin-induced  proteolysis  of the  IL-1 
translation  product  (51,  52)  to  potentially  more  active  forms.  The  role  of 
thrombin as an inducer of IL-1  suggests that activation of coagulation can play 
a role in priming the immune and inflammatory response. Thus, in addition to 
the well-known activation  of coagulation  leading to fibrin deposition,  observed 
in a range of inflammatory lesions, a product of the coagulation system, thrombin, 
can play a role in the regulation of the inflammatory response. 
The  present  data  reflect the  close relationship  between the  hemostatic  and 
inflammatory systems. Perturbation of endothelium by stimuli such as IL-1 leads 
to induction of tissue factor procoagulant activity. Tissue factor promotes initi- 
ation  of coagulation  by priming  the  reactions  leading  to thrombin  formation. 
Thrombin,  by  inducing  endothelial  cell  IL-1  production,  closes  a  circle  of 
interactions between the inflammatory and coagulation systems. 
Summary 
Interleukin  1 (IL-1) is a  potent mediator of inflammatory and  immunologic 
phenomena.  In addition,  IL-I  may be intimately involved in  the regulation  of 
hemostasis, since interaction  of IL-1 with endothelial cells has been reported to 
induce tissue factor activity. We demonstrate that perturbation of the endothelial 
cell  induces  augmented  IL-1  release.  Human  umbilical  vein  endothelial  cells 
perturbed by treatment with lipopolysaccharide produced enhanced amounts of 
IL-1  activity.  IL-1  activity from  lipopolysaccharide-treated  endothelial  cell  su- 
pernatants  could  be  absorbed  by an  antibody  to  IL-1  coupled  to  Sepharose. 
Elaboration of IL-1 activity was dependent on the dose of lipopolysaccharide and 
occurred in a time-dependent manner.  Addition of cycloheximide blocked gen- 
eration of IL-I  activity. A  physiological vessel wall perturbant,  the coagulation 
enzyme thrombin,  induced comparable amounts of IL-1  activity in endothelial 
cell cultures.  This  effect was specific for the enzyme,  since active site-blocked 
thrombin and prothrombin  had no effect on IL-1. In addition,  IL-l-containing 
supernatants  from  thrombin-stimulated  endothelial  cells  induced  tissue  factor 
procoagulant activity in fresh endothelial cell cultures.  Thus, in contrast to the 
multiple, known inhibitory mechanisms that block thrombin procoagulant activ- 
ity, these data suggest a circle of interaction in which thrombin induces endothe- 
lial cell elaboration of IL-1, a mediator of endothelial cell procoagulant activity. 
Endothelial cell production of IL-1 in response to perturbation allows these cells 
to play an integral  role in  the regulation  of the inflammatory  and coagulation 
systems. 
We gratefully acknowledge the technical assistance of Y. Bartos. 
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